Dr. Carsten Schwenke

Education

• PhD in Public Health at the Technical University of Berlin, Germany
  

• Certificate "Biometry" of the University of Dortmund

• Statistics (German diploma) with focus on medicine, studies at the Universities of Dortmund, Bochum, Sheffield and Göttingen
  

• Student worker at the statistical consultancy and analysis center (University of Dortmund) and in the department of medical statistics at the University of Göttingen

                                     

Experience in the pharmaceutical industry

The pharmaceutical industry was my home for more than nine years. In these years I gained thorough experience and expertise in the development of drugs and medical devices, due-diligences and submissions. In addition, I worked in market access as global project leader in specialized therapeutics.
My major working areas were diagnostic imaging, spezialized therapeutics and radiopharmaceutical drugs as well as the area of vaccine development. As biostatistician I supported clinical studies of phases I to IV and participated in the design of development programmes for new drugs.
I am a free-lance statistician in the area of life sciences since 2007. Experience with respect to 'Good Clinical Practice' and knowledge of all relevant guidelines is an essential prerequisite at SCO:SSiS. Since the first benefit dossier in 2011 I have worked intensely in the area of AMNOG benefit dossiers, was envolved in more than 290 procedures and took part in more than 70 oral hearings.

Major areas of expertise

Statistical methods

• Analysis of clustered data

• Analysis of categorical and binary data

• Analysis of repeated measurements

• Linear models

• Design of experiments

Medical research and development

• Clinical studies (Phase II, III and IV)

• Diagnostic studies including "Blinded Readings"

• Regulatoy requirements ("Good-Clinical-Practice" (ICH-GCP), European and US- regulatory systems and guidelines on clinical and non-clinical studies, legal fundamentals of clinical studies

• Market Access (dossiers according to AMNOG, Germany)
  

Memberships in expert networks for life sciences

• Competence network life science (CONELIS, CONELIS Homepage, 2009 - 2023)
  

Memberships in statistical associations

• International Biometrical Society - German region (IBS-DR, IBS Homepage, since 1998, Treasurer and board member of the IBS-DR 2010 to 2014)
  

• Working group pharmaceutical research of the biometrical society (APF, APF Homepage, since 1998)
  

• International Society for Pharmacoeconomics and Outcomes Research (ISPOR, ISPOR Homepage, since 2016)

Written Statements (German AMNOG)

9. Gemeinsame Präsidiumskommission IQWiG der GMDS und IBS-DR. Stellungnahme zum Entwurf der Version 7.0 des IQWiG-Papiers Allgemeine Methoden. Gemeinsame Stellungnahme von GMDS und IBS-DR, 2022.

8. Gemeinsame Präsidiumskommission IQWiG der GMDS und IBS-DR. Stellungnahme zum Entwurf der Version 2.0 des IQTiG-Papiers Methodenaspekte in der Arbeit des IQWIG und IQTIG. Gemeinsame Stellungnahme von GMDS und IBS-DR, 2021.

7. Gemeinsame Präsidiumskommission IQWiG der GMDS und IBS-DR. Stellungnahme zum Entwurf der Version 6.1 des IQWiG-Papiers Allgemeine Methoden. Gemeinsame Stellungnahme von GMDS und IBS-DR, 2021.

6. Gemeinsame Präsidiumskommission IQWiG der GMDS und IBS-DR. Stellungnahme zum Entwurf der Version 6.0 des IQWiG-Papiers Allgemeine Methoden. Gemeinsame Stellungnahme von GMDS und IBS-DR, 2020.

5. Gemeinsame Präsidiumskommission IQWiG der GMDS und IBS-DR. Stellungnahme zum Entwurf der Version 1.0s des IQTiG-Papiers Methodische Grundlagen. Gemeinsame Stellungnahme von GMDS und IBS-DR, 2017.

4. Gemeinsame Präsidiumskommission IQWiG der GMDS und IBS-DR. Stellungnahme zum Entwurf der Version 5.0 des IQWiG-Papiers Allgemeine Methoden. Gemeinsame Stellungnahme von GMDS und IBS-DR, 2016.

3. Bender R, Kuß O, Koch A, Schwenke C, Hauschke D. Anwendung von Prädiktionsintervallen in Meta-Analysen mit zufälligen Effekten. Gemeinsame Stellungnahme von IBS-DR, IQWiG und GMDS, 2014.

2. Schwenke C, Kuß O, Siebert Uwe, Hauschke D. Aktualisierung der Allgemeinen Methoden Version 4.0. Gemeinsame Stellungnahme von GMDS und IBS-DR, 2013.

1. Bender R, Schwenke C, Schmoor C, Hauschke D. Stellenwert von Ergebnissen aus indirekten Vergleichen. Gemeinsame Stellungnahme von IBS-DR, IQWiG und GMDS, 2012.

Selected publications

107. Wiesemann S, Schmitter S, Demir A, Prothmann M, Schwenke C, Chawla A, von Knobelsdorff-Brenkenhoff F, Greiser A, Jin N, Bollache E, Markl M, Schulz-Menger J. Impact of sequence type and field strength (1.5, 3, and 7T) on 4D flow MRI hemodynamic aortic parameters in healthy volunteers. Magn Reson Med. 2020;00: 1–13.

106. Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, Galabova G, Majbour N, Vaikath N, El-Agnaf O, Winter D, Mihailovska E, Mairhofer A, Schwenke C, Staffler G, Medori R. Safety and immunogenicity of the alpha-synclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol 2020; 19: 591-600

105. Czibur A, Ferchaw M, Vazquez D, Mikell S, Schwenke C, Endrikat J. Comparison of 2 CT contrast media injection systems: visual air identification and injector face cleaning. Radiologic Technology 2020 Jan/Feb, Volume 91(3): 214-222

104. Neubauer A, Guthoff-Hagen S, Menzler J, Schwenke C et al. German claims data in rare disease HTA: Diffuse large B-cell lymphoma. International Journal of Technology Assessment in Health Care 2019; 35 Special Issue S1: 87

103. Schwenke C. Auswirkung der anwendungsbegleitenden Datenerhebung auf das AMNOG-Verfahren. GMDS. Presentation at 64. annual meeting of GMDS, Dortmund, 2019

102. Neubauer A, Minartz C, Schwenke C, Kurukulasuriya N, Boehnke A. Real world treatment pathways of diffuse large B-cell lymphoma in German claims data. ISPOR Poster presentation. ISPOR Europe 2019 in Copenhagen, Denmark

101. Wright E, Yasmeen N, Malottki K, Sawyer L, Borg E, Schwenke C, Warren R: Assessing the quality and coherence of network meta-analyses of biologics in plaque proriasis: what does all this evidence synthesis tells us?. ISPOR Poster presentation. ISPOR Europe 2019 in Copenhagen, Denmark

100. Nagel E et al. Magnetic resonance perfusion or fractional flow reseve in coronary disease. N Engl J Med. 2019 June; 380: 2418-28

99. Neubauer A, Minartz C, Schwenke C, Kurukulasuriya N, Boehnke A.: Discrete event simulation model of MOR208 in combination with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Poster presenation at ISPOR 2019, New Orleans, USA

98. Thaa B, Esser M, Schwenke C: Indirekte Vergleiche in der Nutzenbewertung. Market Access & Health Policy 2018; 8(6): 22-24

97. Zech CJ, Schwenke C, Endrikat J.: Diagnostic efficacy and safety of Gadoxetate Disodium vs. Gadobenate Dimeglumine in patients with known or suspected focal liver lesions: resulst of a clinical phase III study. Magn Reson Insights 2019 Feb 18; 12

96. Greese J, Diekhoff T, Sieper J, Schwenke C, Makowski MR, Puddubnyy D, Hamm B, Hermann KGA.: Detection of Sacroliitis by Short-tau inversion recovery and T2-weighted turbo spin echo sequences: results from the SIMACT study. J Rheumatol. 2019 Apr; 46(4): 376-383

95. Gerlinger C, Bamber L, Leverkus F, Schwenke C, Haberland C, Schmidt G, Endrikat J.: Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results. BMX Res Notes 2019 Jan 14; 12(1): 18

94. Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T.: On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. Pharm Stat 2019 Mar; 18(2): 166-183

93. Böhme S, Kupas K, Leverkus F, Schwenke C. (2018) Indirekte Vergleiche in Nutzenbewertungsverfahren: Problemfelder und Lösungsansätze. In: Storm A. (Herausgeber) Beiträge zur Gesundheitsökonomie und Versorgungsforschung (Band 22) - AMNOG-Report 2018. medhochzwei, Heidelberg

92. Funk S, Kermer J, Doganguezel S, Schwenke C, von Knobelsdorff-Brenkenhoff F, Schulz-Menger J.: Quantification of the left atrium applying cardiovascular magnetic resonance in clinical routine. Scand Cardiovasc J. 2018 Apr;52(2):85-92.

91. Buchberger B, Mattivi JT, Schwenke C, Katzer C, Huppertz H, Wasem J.: Critical appraisal of RCTs by 3rd year undergraduates after short courses in EBM compared to expert appraisal. GMS J Med Educ. 2018 May 15;35(2):Doc24.

90. Erb-Eigner K, Asbach P, Ro SR, Haas M, Bertelmann E, Pietsch H, Schwenke C, Taupitz M, Denecke T, Hamm B, Lawaczeck R.: DCE-MR imaging of orbital lesions: diagnostic performance of the tumor flow residence time t calculated by a multi-compartmental pharmacokinetic tumor model based on individual factors. Acta Radiol. 2019 May; 60(5): 643-652

89. Funk S, Kermer J, Doganguezel S, Schwenke C, von Knobelsdorff-Brenkenhoff F, Schulz-Menger J.: Quantification of the left atrium applying cardiovascular magnetic resonance in clinical routine. Scand Cardiovasc J. 2018 Apr;52(2):85-92

88. Schwenke C: Real World Evidence and HTA - Experiences with IQWiG. Baseler Biometrische Section, Presentation, 2018

87. Schwenke C., Schwenke S. (2018) Die frühe Nutzenbewertung von Arzneimitteln gemäß § 35a SGB V. In: Pfannstiel M., Jaeckel R., Da-Cruz P. (eds) Innovative Gesundheitsversorgung und Market Access. Springer Gabler, Wiesbaden

86. Funk S. Kermer J, Doanguezel S, Schwenke C, von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Quantification of the left atrium applying cardiovascular magnetic resonance in clinical routing. Scand Cardiovasc J 2018 Jan 5:1-8

85. Schwenke C. Statistical issues in the German AMNOG process. PSI Webinar 2018

84. Fahlenkamp UL, Diaz Ramirez I, Wagner M, Schwenke C, Huppertz A, Hamm B, Lembcke A. Image quality of low-radiation dose left atrial CT using filtered back projection and an iterative reconstruction algorithm: intra-individual comparison in unselected patients undergoing pulmonary vein isolation. Acta Radiol. 2018 Feb; 59 (2): 161-169

83. Endrikat J, Schwenke C, Vogtlaender K, Dohannish S, Breuer J. Safety profile of gadoxetate disodium in elderly patients (>=65 years). Acta Radiol. 2018 Jan; 59 (1): 81-88

82. Leverkus F, Kupas K, Schwenke C, Voß F. Estimands im HTA Kontext. Präsentation, APF Meeting 24-Nov-2017, Freiburg

81. Schwenke C, Schwenke S, Kupas K. Transferability of study results to the target population in the assessment of additional benefit according to SGB V §35a (AMNOG). Abstract, ISBS CEN 2017, Wien

80. Diekhoff T, Hermann KA, Greese J, Schwenke C, Poddubnyy D, Hamm B, Sieper J: Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Ann Rheum Dis. 2017 Sep;76(9):1502-1508

79. Richau J, Dieringer MA, Traber J, von Knobelsdorff-Brenkenhoff F, Greiser A, Schwenke C, Schulz-Menger J: Effects of heart valve prostheses on phase contrast flow measurements in Cardiovascular Magnetic Resonance - a phantom study. J Cardiovasc Magn Reson. 2017 Jan 16;19(1):5

78. Durmus T, Luhur R, Daqqaq T, Schwenke C, Knobloch G, Huppertz A, Hamm B, Lembcke A: Individual selection of X-ray tube settings in computed tomography coronary angiography: Reliability of an automated software algorithm to maintain constant image quality. Eur J Radiol. 2016 May;85(5):963-71.

77. Knobloch G, Lauff MT, Hirsch S, Schwenke C, Hamm B, Wagner M: Nonenhanced magnetic resonance angiography (MRA) of the calf arteries at 3 Tesla: intraindividual comparison of 3D flow-dependent subtractive MRA and 2D flow-independent non-subtractive MRA. Eur Radiol. 2016 Feb 10.

76. Stein A, Schwenke C, Folprecht G, Arnold D: Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. Clin Colorectal Cancer. 2016 Jun;15(2):e29-39

75. Baur AD, Kunz F, Schwenke C, Pschowski R, Röpke TK, Pavel M, Denecke T: Maximizing Information From Routine Staging Computed Tomography in Functional Neuroendocrine Neoplasms: Are There Findings Indicating the Presence of Carcinoid Heart Disease? J Comput Assist Tomogr. 2016 Mar-Apr; 40(2): 277-82.

74. Töpper A, Polleichtner S, Zagrosek A, Prothmann M, Traber J, Schwenke C, von Knobelsdorff-Brenkenhoff F, Schaarschmidt K, Schulz-Menger J: Impact of surgical correction of pectus excavatum on cardiac function: insights on the right ventricle. A cardiovascular magnetic resonance study†. Interact Cardiovasc Thorac Surg. 2016 Jan;22(1):38-46.

73. Fahlenkamp UL, Wagner M, Nickel D, Adam U, Krueger K, Taupitz M, Schwenke C, Huppertz A: Novel Dynamic Hepatic Magnetic Resonance Imaging Strategy Using Advanced Parallel Acquisition, Rhythmic Breath-Hold Technique, and Gadoxetate Disodium Enhancement. Invest Radiol. 2016 Jan;51(1):33-40.

72. Huppertz A, Lembcke A, Sariali el-H, Durmus T, Schwenke C, Hamm B, Sparmann M, Baur AD: Low Dose Computed Tomography for 3D Planning of Total Hip Arthroplasty: Evaluation of Radiation Exposure and Image Quality. J Comput Assist Tomogr. 2015 Sep-Oct;39(5):649-56.

71. Saake M, Langner S, Schwenke C, Weibart M, Jansen O, Hosten N, Doerfler A: MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T. Eur Radiol. 2016 Mar;26(3):820-8.

70. Schwenke C. Subgruppen in der frühen Nutzenbewertung - Fluch oder Segen? Abstract, 61. Biometrisches Kolloquium der IBS-DR 2015, Dortmund.

69. Endrikat J, Schwenke C, Prince MR: Gadobutrol for contrast-enhanced magnetic resonance imaging in elderly patients: review of the safety profile from clinical trial, post-marketing surveillance, and pharmacovigilance data. Clin Radiol. 2015 Jul;70(7):743-51.

68. Egbers N, Schwenke C, Maxeiner A, Teichgräber U, Franiel T: MRI-guided core needle biopsy of the prostate: acceptance and side effects. Diagn Interv Radiol. 2015 May-Jun;21(3):215-21.

67. Fallenberg EM, Renz DM, Karle B, Schwenke C, Ingod-Heppner B, Reles A, Engelken FJ, Huppertz A, Hamm B, Taupitz M: Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging. Eur Radiol. 2015 Mar;25(3):837-49.

66. Baur AD, Maxeiner A, Franiel T, Kilic E, Huppertz A, Schwenke C, Hamm B, Durmus T: Evaluation of the Prostate Imaging Reporting and Data System for the Detection of Prostate Cancer by the Results of Targeted Biopsy of the Prostate. Invest Radiol. 2014; 49(6): 411-20.

65. Lassel EA, Rao R, Schwenke C, Schoenberg SO, Michaely HJ: Diffusion-weighted imaging of focal renal lesions: a meta-analysis. Eur Radiol. 2014 Jan;24(1):241-9.

64. Lembcke A, Schwenke C, Hein PA, Knobloch G, Durmus T, Hamm B, Huppertz A: High-pitch dual-source CT coronary angiography with low volumes of contrast medium. Eur Radiol. 2014 Jan;24(1):120-7.

63. Werner SG, Langer HE, Schott P, Bahner M, Schwenke C, Lind-Albrecht G, Spiecker F, Kurtz B, Burmester GR, Backhaus M: Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging. Arthritis Rheum. 2013 Dec;65(12):3036-44.

62. Durmus T, Goldmann U, Baur AD, Huppertz A, Schwenke C, Hamm B, Franiel T: MR-guided biopsy of the prostate: comparison of diagnostic specimen quality with 18 G and 16 G biopsy needles. Eur J Radiol. 2013 Dec;82(12):e749-54.

61. Durmus T, Vollnberg B, Schwenke C, Kilic E, Huppertz A, Taupitz M, Franiel T: Dynamic Contrast Enhanced MRI of the Prostate: Comparison of Gadobutrol and Gd-DTPA. Rofo. 2013 Sep;185(9):862-8

60. Koenig M, Schulte-Altedorneburg G, Piontek M, Hentsch A, Spangenberg P, Schwenke C, Harders A, Heuser L: Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read. Eur Radiol. 2013 Dec; 23 (12): 3287-95.

59. Fahlenkamp UL, Lembcke A, Roesler R, Schwenke C, Huppertz A, Streitparth F, Taupitz M, Hamm B, Wagner M: ECG-gated imaging of the left atrium and pulmonary veins: Intra-individual comparison of CTA and MRA. Clin Radiol. 2013; 68(10): 1059-64.

58. Koenig M, Schulte-Altedorneburg G, Piontek M, Hentsch A, Spangenberg P, Schwenke C, Harders A, Heuser L. Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read. Eur Radiol. 2013; 23(12): 3287-3295

57. von Knobelsdorff-Brenkenhoff F, Prothmann M, Dieringer MA, Wassmuth R, Greiser A, Schwenke C, Niendorf T, Schulz-Menger J. Myocardial T1 and T2 mapping at 3 T: reference values, influencing factors and implications. J Cardiovasc Magn Reson. 2013 Jun 18;15(1):53.

56. Schwenke C: How to demonstrate the added value of diagnostic tests. Abstract, DAGStat 2013, Freiburg

55. Wagner M, Schilling R, Doeblin P, Huppertz A, Luhur R, Schwenke C, Maurer M, Hamm B, Taupitz M, Durmus T: Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine. Eur Radiol. 2013 Jan; 23(1):108-14

54. Pediconi F, Kubik-Huch R, Chilla B, Schwenke C and Kinkel K: Intra-individual randomized comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for preoperative breast MRI. Eur Radiol. 2013 Jan; 23(1):84-92

53. Werner SG, Langer H-E, Ohrndorf S, Bahner M, Schott P, Schwenke C, Schirner M, Bastian H, Lind-Albrecht G, Kurtz B, Burmester GR, Backhaus M: Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis 2012, 71(4): 504-510

52. Schwenke C: Kategorien der Ergebnissicherheit beim Zusatznutzen. Presentation, Workshop Arbeitsgruppe Pharmazeutische Forschung der IBS-DR, November 16, 2012, Hochheim, Germany

51. Schwenke C: Gibt es einen Zusatznutzen durch die Einführung der Kategorie „Anhaltspunkt" zur Beschreibung der Ergebnissicherheit?. Abstract, IQWiG im Dialog, 22. Juni 2012

50. Meyer C. Ludolph AC, Landwehrmeyer B, Schwenke C, Doble A and Orth M: Rate of change in early Huntington's disease: a clinicometric analysis. Mov Disord. 2012; 27(1): 118-24

49. Bolognese L, Falsini G, Schwenke C, Grotti S, Limbruno U, Liistro F, Carrera A, Angioli P, Picchi A, Ducci K, Pierli C: Impact of Iso-Osmolar Versus Low-Osmolar Contrast Agents on Contrast-Induced Nephropathy and Tissue Reperfusion in Unselected Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (From the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial). Am J Cardiol. 2012: 109(1): 67-74 

48. Werner SG, Langer H-E, Ohrndorf S, Bahner M, Schott P, Schwenke C, Schirner M, Bastian H, Lind-Albrecht G, Kurtz B, Burmester GR, Backhaus M: Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis 2012, 71(4): 504-10

47. Boldt LH, Schwenke C, Parwani AS, Huemer M, Wutzler A, Haverkamp W: Determinants of mortality in patients with heart failure and atrial fibrillation during long-term follow-up. Acta Cardiol. 2011 Dec;66(6):751-7.

46. Boyé P, Abdel-Aty H, Zacharzowsky U, Bohl S, Schwenke C, van der Geest RJ, Dietz R, Schirdewan A, Schulz-Menger J: Prediction of life-threatening arrhythmic events in patients with chronic myocardial infarction by contrast-enhanced CMR. JACC Cardiovasc Imaging. 2011 Aug;4(8):871-9.

45. Orth M, Schwenke C: Age-at-onset in Huntington disease. PLoS Curr. 2011 Jul 29: RRN1258

44. Werner S, Schott P, Ohrndorf S, Schwenke C, Bahner M, Kurtz B, Backhaus M, Burmester GR, Langer H-E: Sensitivity and Specificity of ICG-enhanced Optical Imaging (Xiralite) in Comparison to MRI and Ultrasonography, Abstract, ACR, 2011

43. Werner S, Spieker F, Lind-Albrecht G, Schwenke C, Langer H-E: Indocyanine green enhanced optical imaging using for monitoring of treatment response, Abstract, ACR, 2011

42. Werner S, Langer H-E, Spieker F, Schwenke C: Entwicklung einer standardisierten Bildanalyse für das Xiralite-Verfahren und Intra- sowie Interreader-Reliabilität, Abstract, DGRh, 2011, Munich

41. Werner S, Schott P, Bahner M, Schwenke C, Kurtz B, Lind-Albrecht G, Backhaus M, Burmester G, Langer H-E: ICG-gestützte fluoreszenzoptische Bildgebung im Vergleich zur klinischen Untersuchung und Kernspintomographie bei Patienten mit rheumatoider oder undifferenzierter Arthritis, Abstract, DGRh, 2011, Munich

40. Werner S, Ohrndorf S, Langer H-E, Bahner M, Schwenke C, Burmester G, Backhaus M: Comparison of Xiralite with Clinical Examination and Ultrasonography. Abstract and Poster, EULAR 2011, London

39. Koch A, Hamann L, Schott M, Boehm O, Grotemeyer D, Kurt M, Schwenke C, Schumann RR, Bornstein SR, Zacharowski K: Genetic variation of TLR4 influences immunoendocrine stress response: an observational study in cardiac surgical patients. Critical Care 2011; 15(2): R109

38. Pennekamp W, Roggenland D, Hering S, Lemburg S, Peters S, Sterl S, Schwenke C, Nicolas V: Intra-individual, randomised comparison of the MRI contrast agents gadobutrol and gadoterate in imaging the distal lower limb of patients with known or suspected osteomyelitis, evaluated in an off-site blinded read. Eur Radiol. 2011; 21(5):1058-1067

37. Voth M, Attenberger UI, Luckscheiter A, Haneder S, Henzler T, Schoenberg SO, Schwenke C, Michaely HJ: "Number needed to read" - How to facilitate clinical trials in MR-angiography. Eur Radiol. 2011; 21(5):1034-1042

36. Möckel M, Dümichen M, Friedrich K, Kühnle Y, Vollert JO, Searle J, Combé V, Schwenke C, Schröder M: Invasive renal hemodynamics after left ventricular and coronary angiography with randomized use of different contrast media, Abstract, Euro-PCR, May 2011

35. Richter WS, Ivancevic V, Meller J, Lang O, Le Guludec D, Szilvazi I, Amthauer H, Chossat F, Dahmane A, Schwenke C, Signore A: (99m)Tc-besilesomab (Scintimum®) in peripheral osteomyelitis: comparison with (99m)Tc-labelled white blood cells. Eur J Nucl Med Mol Imaging 2011; 38(5): 899-910.

34. Wagner M, Rösler R, Lembcke A, Butler C, Dewey M, Laule M, Huppertz A, Schwenke C, Warmuth C, Rief M, Hamm B, Taupitz M: Whole-heart coronary magnetic resonance angiography at 1.5 tesla: does a blood-pool contrast agent improve diagnostic accuracy?. Invest Radiol. 2011; 46(3): 152-159

33. Voth M, Michaely HJ, Schwenke C, Vos B, Pietsch H: Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla. Eur Radiol. 2011; 21(2): 337-344

32. Huppertz A, Radmer S, Asbach P, Juran R, Schwenke C, Diederichs G, Hamm B, Sparmann M: Computed tomography for preoperative planning in minimalinvasive total hip arthroplasty: Radiation exposure and cost analysis. Eur J Radiol 2011; 78(3): 406-13

31. Huppertz A, Franiel T, Wagner M, Püttcher O, Wagner J, Rief M, Schwenke C, Hamm B, Strassburg J: Whole-body MRI with assessment of hepatic and extraabdominal enhancement after administration of gadoxetic acid for staging of rectal carcinoma. Acta Radiol. 2010 Oct;51(8):842-50.

30. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB, Investigators of the European Huntington's Disease Network: Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. J Neurol Neurosurg Psychiatry 2011; 82(12): 1409-12

29. Schwenke C, Boos M, Hentrich R, Blankenburg M, Rohrer M.: Angiography for diagnosing peripheral arterial occlusive disease - a technical, clinical and cost comparison of contrast-enhanced magnetic resonance angiography and unenhanced magnetic resonance imaging techniques with a focus on fresh blood imaging. Eur Cardiology 2010; 6(2):54-60

28. Rief M, Huppertz A, Asbach P, Franiel T, Schwenke C, Hamm B, Taupitz M, Wagner M: Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement. Invest Radiol. 2010 Sep;45(9):565-71.

27. Bergmann K, Lungershausen J and Schwenke C: Angiographie for diagnosing PAOD: cost comparison of the diagnostic procedures MRA and DSA. Abstract and Poster, ISPOR 2009, Paris

26. Ho AK, Schwenke C, EHDN contributors: Quality of life and carer burden in Huntington's disease. Abstract, WCHD 2009, Sep 12-15, Vancover

25. Meyer C. Ludolph AC, Landwehrmeyer B, Schwenke C, Doble A and Orth M: Modification of the unified Huntington's disease rating scale: selection of items on the basis of the EHDI data. Abstract, WCHD 2009, Sep 12-15, Vancover

24. Meyer C. Ludolph AC, Landwehrmeyer B, Schwenke C, Doble A and Orth M: Rate of change in early Huntington's disease: a three year prospective study not confounded by the effects of antipsychotics. Abstract, WCHD 2009, Sep 12-15, Vancover

23. Schwenke C: Simultaneous consideration of sensitivity and specificty in bivariate metaanalyses - hands-on experience. Abstract, 55. Biometrisches Kolloquium, March 17-19, Internationale Biometrische Gesellschaft Deutsche Region, 2009, Hannover

22. Saupe N, Zanetti M, Pfirrmann C, Wels T, Schwenke C and Hodler J: Pain and other side effects after MR arthrography: prospective evaluation in 1085 patients. Radiology 2009; 250(3): 830-838

21. Schwenke C, Kienbaum S and Bergmann K: Health Economic Assessment of Vasovist - Technical, Clinical and Cost Benefits, In: Clinical Blood Pool MR Imaging, Leiner T, Goyen M, Rohrer M and Schönberg S (Eds.), Springer Medizin Verlag, Heidelberg, 2008

20. Schwenke C: Sample size estimation for cluster-randomized clinical trials. Abstract, 54. Biometrisches Kolloquium, March 10-13, Internationale Biometrische Gesellschaft Deutsche Region, 2008, Munich

19. Schwenke C: True Positives, True Negatives, False Positives, False Negatives. In: Chow S-C, Liu J-P: Encyclopedia of Clinical Trials, John Wiley & Sons, New York, 2008

18. Schwenke C: Diagnostic studies. In: Chow S-C, Liu J-P: Encyclopedia of Clinical Trials, John Wiley & Sons, New York, 2008

17. Schwenke C, Busse R. Analysis of differences in proportions from clustered data with multiple measurements in diagnostic studies. Methods of Information in Medicine, 2007; 46: 548-552

16. Kaufmann J, Chang S, Schwenke C: Simultaneous comparisons of accuracy, sensitivity, and specificity in diagnostic trials: closed test procedures with a-priori ordered hypotheses. Abstract, XXIII International Biometric Conference, July 16 - 21, 2006, Montréal, Québec, Canada

15. Kaufmann J, Schwenke C: A two way design to analyze efficacy indices – accuracy, sensitivity, specificity - in diagnostic studies. Abstract, Meeting "Evaluation im Gesundheitswesen", March 6-9, 2006, Bochum

14. Schwenke C, Kaufmann J: Differences in proportions from clustered data with multiple measurements per observational unit. Abstract, Meeting "Evaluation im  Gesundheitswesen", March 6-9, 2006, Bochum

13. Schwenke C, Kaufmann J: QT/RR Hysteresis in QT Prolongation StudiesExemplarily for a new MR Contrast Agent. Abstract, Meeting of the "Abteilung Medizinische Statistik der Internationalen Biometrischen Gesellschaft Deutsche Region", November 17-18, 2005, Heidelberg

12. Schwenke C: Analysis of multiple reader studies with clustered binary data. Abstract, "BfArM im Dialog", November 11-12, 2005, Bonn

11. Kaufmann J, Schwenke C: The statistical analysis of cluster randomization trials. Abstract, 51. Biometrisches Kolloquium, March 21-23, Internationale Biometrische Gesellschaft Deutsche Region, 2005, Halle (Saale)

10. Schwenke C, Nevalainen J: Handling missing observations in the estimation of proportions from clustered data in a matched-pair design. Abstract, Joint Statistical Meetings, August 8-12, 2004, American Statistical Association, Biometrics section, Toronto, Canada

9. Schwenke C, Nevalainen J: Analysis of proportions from clustered data with missing data in a matched-pair design. Methods of Information in Medicine, 2004; 43: 521-524

8. Schwenke C: A two-step procedure for the analysis of blinded reader studies with multiple observations per patient. Presentation at Biometrisches Kolloquium "Statistische Methoden in der empirischen Forschung", November 25, 2003, Berlin, Germany

7. Schwenke C: Biometrie in der Arzneimittelentwicklung - Rolle und Aufgaben des Biometrikers in der pharmazeutischen Industrie. Presentation at 2. Berliner MNU Kongress, September 4-5, 2003, Berlin, Germany

6. Schwenke C, Kaufmann J: Analysis of blinded reader studies: Correlated proportions for clustered data with repeated measurements, 2003 Proceedings of the American Statistical Association, Biometrics section [CD-ROM], Alexandria, VA: American Statistical Association

5. Malfertheiner P, Schultze V, Del Guidice G, Rosenkranz B, Kaufmann S H E, Winau F, Ulrichs T, Theophil E, Pagel Jue C, Novicki D, Norelli F, Contorni M, Berti D, Lin J-S, Schwenke C, Goldman M, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt B F: Phase I Safety and Immunogenicity of a Three-Compound H. pylori Vaccine. Poster Presentation: American Gastroenterology Association, Annual Meeting at Digestive Disease Week, May 19-22, 2002, San Francisco, CA, USA

4. Banzhoff A, Schwenke C, Febbraro S: Preservative-Free Influenza Vaccine. Immunology Letters, 71, 2000, Elsevier Science B.V., pp. 91-96.

3. Banzhoff A, Schwenke C, Bröker M: Immunogenicity and Tolerability of a Preservative-Free Influenza Vaccine. 10th European Congress of Clinical Microbiology and Infectious Diseases, May 28 - 31. 2000, Stockholm, Schweden.

2. Banzhoff A, Donner-Banzhoff N, Schwenke C, Girgsdies O-E, Jilg W: Combination Against Polio, Diphtheria and Tetanus. A Randomized controlled Study to evaluate Immunogenicity and Tolerability. Eränzungsband der MMW-Fortschr. Med. 118. Jg., Originalien IV/2000, pp. 169-172.

1. Banzhoff A, Donner-Banzhoff N, Schwenke C, Girgsdies O-E, Jilg W: Kombinationsimpfstoff gegen Polio, Diphtherie und Tetanus: Damit schließen Sie Impflücken.  MMW-Fortschr. Med. Originalie, Nr. 48 / 2000, p. 54.